RayKnowChina Research Map
Shortlist

Hangzhou

Hangzhou First People's Hospital

杭州市第一人民医院

Listed for 22 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Hangzhou First People's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌8 papers led
  2. Hepatocellular carcinoma肝细胞癌67 papers led
  3. Stomach cancer胃癌11 papers led
  4. Lung cancer肺癌51 papers led
  5. Pancreatic cancer胰腺癌23 papers led1 open trial led
  6. Breast cancer乳腺癌21 papers led
  7. Glioma胶质瘤8 papers led
  8. Retinoblastoma视网膜母细胞瘤1 paper led
  9. Osteosarcoma骨肉瘤3 papers led
  10. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  11. Multiple myeloma多发性骨髓瘤5 papers led
  12. Lymphoma淋巴瘤7 papers led
  13. Coronary heart disease冠心病16 papers led
  14. Congenital heart disease先天性心脏病1 paper led
  15. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  16. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  17. Fabry disease法布雷病1 paper led
  18. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  19. Behçet disease白塞病1 paper led
  20. IgA nephropathyIgA 肾病0 papers led
  21. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  22. Leber hereditary optic neuropathyLeber 遗传性视神经病变0 papers led

Not listed for: Oesophageal squamous cell carcinoma, Hepatoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 8 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 2220242025: 222025

8 hospitals in Hangzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & AIRadiotherapy techniqueSide effects & quality of life
Departments in papersENT / head & neck surgeryRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 67 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
67
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 131320212022: 191920222023: 151520232024: 8820242025: 11112025

7 hospitals in Hangzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionSurgery & liver transplant
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineMedical oncologyClinical trials / research unit
Papers it led67
  1. Disphosphate based hydrogel microspheres for targeted transarterial radioembolization and chemoembolization therapies.2026Journal of advanced researchFree full text
  2. Mitochondria-Targeted Icaritin Nanoparticles Induce Immunogenic Cell Death in Hepatocellular Carcinoma.2025ACS applied materials & interfaces
  3. Hepatic Arterial Infusion Chemotherapy Enhances the Efficacy of Lenvatinib Plus PD-1 Inhibitors in Hepatocellular Carcinoma Patients with Tumor Thrombosis in the Inferior Vena Cava and/or Right Atrium.2025Academic radiology
  4. A Novel tRF, HCETSR, Derived From tRNA-Glu/TTC, Inhibits HCC Malignancy by Regulating the SPBTN1-catenin Complex Axis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. Deciphering the Role of Necroptosis-Related Long Non-coding RNAs in Hepatocellular Carcinoma: A Necroptosis-Related lncRNA-Based Signature to Predict the Prognosis of Hepatocellular Carcinoma.2025Applied biochemistry and biotechnology
  6. Long non-coding RNA in hepatocellular carcinoma: mechanistic insights and therapeutic perspectives.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  7. HCC-derived CX3CL1 affects hepatocellular carcinoma prognosis and CX3CR1 + MDSC infiltration.2025European journal of medical researchFree full text
  8. METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.2025Future oncology (London, England)Free full text
  9. Impact of Donor CMV-Seropostive Grafts on Prognosis of Liver Transplantation for Hepatocellular Carcinoma.2025Journal of medical virology
  10. Multi-omic analysis reveals elevated BRI3BP expression associated with hepatocellular carcinoma progression and poor prognosis.2025Scientific reportsFree full text
  11. Unraveling the Causal Links Between Immune Traits and Hepatocellular Carcinoma: Insights From a Bi-Directional Mendelian Randomization Study.2025The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  12. G-LERP/miR-374i-b Attenuates IRI and Suppresses Hepatocellular Carcinoma Progression.2025Transplantation
  13. Microchip Based Isolation and Drug Delivery of Patient-Derived Extracellular Vesicles Against Their Homologous Tumor.2024Advanced healthcare materials
  14. Is DEB-TACE as locoregional therapy before liver transplantation for hepatocellular carcinoma effective?2024BMC gastroenterologyFree full text
  15. Hepatocellular carcinoma-specific epigenetic checkpoints bidirectionally regulate the antitumor immunity of CD4 + T cells.2024Cellular & molecular immunologyFree full text
  16. Heterogeneity of hepatocellular carcinoma that responds differently to combination therapy with TACE and Sorafenib as determined by digital spatial gene expression profiling.2024Genes & genomics
  17. Ferroptosis-inducing nanomedicine and targeted short peptide for synergistic treatment of hepatocellular carcinoma.2024Journal of nanobiotechnologyFree full text
  18. Ferroptosis: a new promising target for hepatocellular carcinoma therapy.2024Molecular and cellular biochemistry
  19. mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma.2024Molecular biomedicineFree full text
  20. Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma.2024The British journal of radiologyFree full text
  21. Preoperative Nomogram Incorporating Clinical Factors, Serological Markers and LI-RADS MRI Features to Predict Early Recurrence of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.2023Academic radiology
  22. SSNA1 Promotes Hepatocellular Carcinoma Metastasis Via STAT3/EMT Induction.2023Anticancer research
  23. Scribble promotes fibrosis-dependent mechanisms of hepatocarcinogenesis by p53/PUMA-mediated glycolysis.2023Biochimica et biophysica acta. Molecular basis of disease
  24. Protein induced by vitamin K absence or antagonist II: Experience to date and future directions.2023Biochimica et biophysica acta. Reviews on cancer
  25. Vertically-Ordered Mesoporous Silica Film Based Electrochemical Aptasensor for Highly Sensitive Detection of Alpha-Fetoprotein in Human Serum.2023BiosensorsFree full text
  26. BMI1-induced CD127+KLRG1+ memory T cells enhance the efficacy of liver cancer immunotherapy.2023Cancer letters
  27. Systemic analysis identifying PVT1/DUSP13 axis for microvascular invasion in hepatocellular carcinoma.2023Cancer medicineFree full text
  28. ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1.2023Cell communication and signaling : CCSFree full text
  29. A mixed blessing for liver transplantation patients - Rapamycin.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  30. Prognostic implication of early posttransplant hypercholesterolemia in liver transplantation for patients with hepatocellular carcinoma.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  31. SULT2B1-CS-DOCK2 axis regulates effector T-cell exhaustion in HCC microenvironment.2023Hepatology (Baltimore, Md.)
  32. Current Status and Prospect of Delivery Vehicle Based on Mesenchymal Stem Cell-Derived Exosomes in Liver Diseases.2023International journal of nanomedicineFree full text
  33. Serum Exosome-Derived piRNAs Could Be Promising Biomarkers for HCC Diagnosis.2023International journal of nanomedicineFree full text
  34. Identification of a brand intratumor microbiome signature for predicting prognosis of hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  35. The predictive value of the modified AFP model for liver transplantation outcomes in multinodular hepatocellular carcinoma patients.2023World journal of surgical oncologyFree full text
  36. Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression.2022Acta pharmaceutica (Zagreb, Croatia)
  37. E2F7 promotes mammalian target of rapamycin inhibitor resistance in hepatocellular carcinoma after liver transplantation.2022American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  38. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.2022BMC cancerFree full text
  39. Identification and Verification of a Novel MAGI2-AS3/miRNA-374-5p/FOXO1 Network Associated with HBV-Related HCC.2022CellsFree full text
  40. Clinical practice guideline on liver transplantation for hepatocellular carcinoma in China (2021 edition).2022Chinese medical journalFree full text
  41. RNA binding protein-based risk score model for prognosis prediction of patients with hepatocellular carcinoma.2022Chinese medical journalFree full text
  42. Long-term outcomes of deceased donor liver transplantation in hepatocellular carcinoma patients with portal vein tumor thrombus: A multicenter study.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  43. Reply to 'How to select eligible hepatocellular carcinoma patients with portal vein tumor thrombus for deceased donor liver transplantation?'.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  44. One Shoot, Two Birds: Alleviating Inflammation Caused by Ischemia/Reperfusion Injury to Reduce the Recurrence of Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  45. Methylation site APC112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence.2022Future oncology (London, England)
  46. Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  47. Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study.2022Hepatology internationalFree full text
  48. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?2022International journal of biological sciencesFree full text
  49. DYRK1A reinforces epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma via cooperatively activating STAT3 and SMAD.2022Journal of biomedical scienceFree full text
  50. Tumor-suppressive role of microfibrillar associated protein 4 and its clinical significance as prognostic factor and diagnostic biomarker in hepatocellular carcinoma.2022Journal of cancer research and therapeutics
  51. Comment on "Predictors of changes in preoperative tumor stage between dynamic computed tomography and gadoxetate disodium-enhanced magnetic resonance imaging for hepatocellular carcinoma".2022Journal of the Formosan Medical Association = Taiwan yi zhi
  52. Association of RASSF1A Ala133Ser polymorphism with cancer risk: a updated meta-analysis involving 7362 subjects.2022Nucleosides, nucleotides & nucleic acids
  53. Multi-omics profiling reveals Chitinase-3-like protein 1 as a key mediator in the crosstalk between sarcopenia and liver cancer.2022Redox biologyFree full text
  54. CLIC1 Drives Angiogenesis in Hepatocellular Carcinoma by Modulating VEGFA.2022Technology in cancer research & treatmentFree full text
  55. Value of Gd-EOB-DTPA-Enhanced MRI and Diffusion-Weighted Imaging in Detecting Residual Hepatocellular Carcinoma After Drug-Eluting Bead Transarterial Chemoembolization.2021Academic radiology
  56. Interleukin-2 inducible T-cell kinase: a potential prognostic biomarker and tumor microenvironment remodeling indicator for hepatocellular carcinoma.2021AgingFree full text
  57. Effects of terlipressin and somatostatin on liver function after major hepatectomy for hepatocellular carcinoma.2021Asian journal of surgery
  58. C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1).2021Biological chemistry
  59. The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib.2021Cell death & diseaseFree full text
  60. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.2021Clinical radiology
  61. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  62. Risk factors associated with suicide among hepatocellular carcinoma patients: A surveillance, epidemiology, and end results analysis.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyFree full text
  63. Key factors and potential drug combinations of nonalcoholic steatohepatitis: Bioinformatic analysis and experimental validation-based study.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  64. Genome-Wide Profiling of Alternative Splicing Signatures Associated with Prognosis and Immune Microenvironment of Hepatocellular Carcinoma.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  65. LncRNA MEG8 plays an oncogenic role in hepatocellular carcinoma progression through miR-367-3p/14-3-3ζ/TGFβR1 axis.2021Neoplasma
  66. Combination therapy for HCC: from CRISPR screening to the design of clinical therapies.2021Signal transduction and targeted therapyFree full text
  67. Downstaging treatment for patients with hepatocelluar carcinoma before transplantation.2021Transplantation reviews (Orlando, Fla.)
Chinese-language papers (not in the count)2
  1. [Novel research horizon for liver transplantation management model in hepatocellular carcinoma based on the tumor-donor liver-recipient].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. Deep learning-based radiomics allows for a more accurate assessment of sarcopenia as a prognostic factor in hepatocellular carcinoma.2024Journal of Zhejiang University. Science. BFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular CarcinomaCompletedNCT05907772Study siteStart 2022-08
  2. Impact of Gender on the Outcome of Liver Transplantation for Hepatocellular CarcinomaCompletedNCT05643833Study siteStart 2021-01

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 11 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 0020222023: 2220232024: 2220242025: 332025

9 hospitals in Hangzhou for stomach cancer211 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseSurgeryChemotherapy & combined treatment
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncologyPathology / laboratory medicine
Papers it led11
  1. Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer.2025Annals of medicineFree full text
  2. Immunotherapy Combined with Chemotherapy in the First-Line Treatment of Advanced Gastric Cancer: Systematic Review and Bayesian Network Meta-Analysis Based on Specific PD-L1 CPS.2025Current oncology (Toronto, Ont.)Free full text
  3. The mir-371a-373 cluster: A crucial miRNA cluster promotes the malignancy of gastric cancer.2025Neoplasma
  4. The relationship between innate/adaptive immunity and gastrointestinal cancer : a multi-omics Mendelian randomization study.2024BMC gastroenterologyFree full text
  5. Comprehensive analysis of the expression, prognostic, and immune infiltration for COL4s in stomach adenocarcinoma.2024BMC medical genomicsFree full text
  6. Vernodalin Suppresses Tumor Proliferation and Increases Apoptosis of Gastric Cancer Cells Through Attenuation of FAK/PI3K/AKT/mTOR and MAPKs Signaling Pathways.2023Current pharmaceutical biotechnology
  7. The putative role of ferroptosis in gastric cancer: a review.2023European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)Free full text
  8. Efficiency of complete omentectomy in patients with resectable gastric cancer: a meta‑analysis and systematic review.2021BMC gastroenterologyFree full text
  9. A population-based analysis of malignant gastric tumor in children.2021Journal of pediatric surgery
  10. Double Gastroscopy Resection Is a New Attempt to Treat Gastric Submucosal Tumors: A Case Report.2021The American journal of gastroenterology
  11. Exosomal NNMT from peritoneum lavage fluid promotes peritoneal metastasis in gastric cancer.2021The Kaohsiung journal of medical sciencesFree full text
Chinese-language papers (not in the count)1
  1. [Clinicopathological analysis of amphicrine carcinoma of the stomach].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status7
  1. Treatment of Advance Gastric Cancer With DisulfiramStatus unknownNCT05667415Study siteN/AStart 2023-06
  2. A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)TerminatedNCT04933227Study sitePhase 2Start 2021-08
  3. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  4. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12
  5. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  6. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  7. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Study sitePhase 2/Phase 3Start 2012-09

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 51 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
51
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 9920212022: 7720222023: 9920232024: 141420242025: 12122025

11 hospitals in Hangzhou for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06862869

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineMedical oncologySurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led51
  1. Rapid and Noninvasive Early Detection of Lung Cancer by Integration of Machine Learning and Salivary Metabolic Fingerprints Using MS LOC Platform: A Large-Scale Multicenter Study.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Identification and functional characterization of genes associated with lipopolysaccharide in lung adenocarcinoma.2025BMC cancerFree full text
  3. Blood-brain barrier alterations as an initiator of brain metastasis from lung cancer: a new take on an old story.2025Cancer gene therapy
  4. Assessing the carcinogenic potential and molecular mechanisms of arecoline in human lungs: from in silico methods to in vitro validation.2025Ecotoxicology and environmental safety
  5. Toripalimab plus chemotherapy as first-line treatment in extensive-stage small cell lung cancer: a health economic evaluation in China.2025Frontiers in public healthFree full text
  6. Investigating the role of IDO1 in tumors: correlating IDO1 expression with clinical pathological features and prognosis in lung adenocarcinoma patients.2025PeerJFree full text
  7. Investigating the correlation between IDO1/PD-L1 expression or co-expression and EGFR/KRAS gene mutations in advanced NSCLC.2025Scientific reportsFree full text
  8. Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis.2025Scientific reportsFree full text
  9. TtAgo-coupled-multiplex-digtal-RPA-CRISPR/Cas12a (TCMDC) for EGFR mutations detection.2025Talanta
  10. The study of transitional care on the psychological state of patients with advanced lung cancer chemotherapy.2025Technology and health care : official journal of the European Society for Engineering and Medicine
  11. Hepatic metastasis of pulmonary large cell neuroendocrine carcinoma: A case report and literature review.2025The Journal of international medical researchFree full text
  12. Phosphodiesterase 1A physically interacts with YTHDF2 and reinforces the progression of non-small cell lung cancer.2025eLifeFree full text
  13. SEPT9: From pan-cancer to lung squamous cell carcinoma.2024BMC cancerFree full text
  14. Suppression of PERK/eIF2α/CHOP pathway enhances oridonin-induced apoptosis by inhibiting autophagy in Small-Cell lung cancer cells.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  15. Comprehensive utilization of in silico approach and in vitro experiment to unveil the molecular mechanisms of mono (2-ethylhexyl) phthalate-induced lung adenocarcinoma.2024Bioorganic chemistry
  16. Advances in Research on the Anticancer Properties and Mechanisms of Metformin in Lung Cancer.2024British journal of hospital medicine (London, England : 2005)
  17. Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming.2024Cancer control : journal of the Moffitt Cancer CenterFree full text
  18. ITGB4 is a prognostic biomarker and correlated with lung adenocarcinoma brain metastasis.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  19. Functional Characterization of Reduced Folate Carrier and Protein-Coupled Folate Transporter for Antifolates Accumulation in Non-Small Cell Lung Cancer Cells.2024Drug metabolism and disposition: the biological fate of chemicals
  20. A Radiological-Radiomics model for differentiation between minimally invasive adenocarcinoma and invasive adenocarcinoma less than or equal to 3 cm: A two-center retrospective study.2024European journal of radiology
  21. Long-term survival of stage Ib lung adenocarcinoma with postoperative brain oligometastasis: a case report and literature review.2024Folia neuropathologica
  22. Detection of serum SNHG22 and its correlation with prognosis of non-small cell lung cancer.2024Journal of cardiothoracic surgeryFree full text
  23. Taxus chinensis var. mairei (Lemée et Lévl) Cheng et L.K. Fu overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer via suppression of ERK1/2-related cholesterol biosynthesis.2024Journal of ethnopharmacology
  24. Potential of Targeting TDO2 as the Lung Adenocarcinoma Treatment.2024Journal of proteome research
  25. Oleandrin enhances radiotherapy sensitivity in lung cancer by inhibiting the ATM/ATR-mediated DNA damage response.2024Phytotherapy research : PTR
  26. SPTBN2 suppresses ferroptosis in NSCLC cells by facilitating SLC7A11 membrane trafficking and localization.2024Redox biologyFree full text
  27. Scribble promotes fibrosis-dependent mechanisms of hepatocarcinogenesis by p53/PUMA-mediated glycolysis.2023Biochimica et biophysica acta. Molecular basis of disease
  28. Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation.2023Chemico-biological interactions
  29. CISD2 promotes lung squamous carcinoma cell migration and invasion via the TGF-β1-induced Smad2/3 signaling pathway.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  30. MFN2 deficiency affects calcium homeostasis in lung adenocarcinoma cells via downregulation of UCP4.2023FEBS open bioFree full text
  31. The second-generation tyrosine kinase inhibitor afatinib inhibits IL-1β secretion via blocking assembly of NLRP3 inflammasome independent of epidermal growth factor receptor signaling in macrophage.2023Molecular immunology
  32. A novel risk signature for predicting brain metastasis in patients with lung adenocarcinoma.2023Neuro-oncologyFree full text
  33. Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.2023Thoracic cancerFree full text
  34. Characterization and mechanisms of radioresistant lung squamous cell carcinoma cell lines.2023Thoracic cancerFree full text
  35. Lung cancer patient with Tropheryma whipplei and Nocardia co-infection.2023Ultrastructural pathology
  36. Lung cancer metastasis-related protein 1 promotes the transferring from advanced metastatic prostate cancer to castration-resistant prostate cancer by activating the glucocorticoid receptor α signal pathway.2022BioengineeredFree full text
  37. SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer.2022Cancer letters
  38. Hope and Worry: An Interpretative Phenomenological Analysis of Psychological Experiences Associated With Targeted Drug Therapy Among Patients With Advanced Non-Small-Cell Lung Cancer.2022Cancer nursing
  39. TNFα antagonist in combination with PD-1 blocker to prevent or retard malignant transformation of B[a]P-induced chronic lung inflammation.2022Carcinogenesis
  40. Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.2022International journal of oncologyFree full text
  41. Pulsatilla saponin E suppresses viability, migration, invasion and promotes apoptosis of NSCLC cells through negatively regulating Akt/FASN pathway via inhibition of flotillin-2 in lipid raft.2022Journal of receptor and signal transduction research
  42. Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer.2022Tissue & cell
  43. Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT.2021Acta pharmacologica SinicaFree full text
  44. GTSE1 Facilitates the Malignant Phenotype of Lung Cancer Cells via Activating AKT/mTOR Signaling.2021Analytical cellular pathology (Amsterdam)Free full text
  45. Effect of continuous nursing based on the Omaha System on cancer-related fatigue in patients with lung cancer undergoing chemotherapy: a randomized controlled trial.2021Annals of palliative medicineRCT
  46. LASP1 Induces Epithelial-Mesenchymal Transition in Lung Cancer through the TGF-β1/Smad/Snail Pathway.2021Canadian respiratory journalFree full text
  47. Specific Gut Microbiome and Serum Metabolome Changes in Lung Cancer Patients.2021Frontiers in cellular and infection microbiologyFree full text
  48. Downregulation of breast cancer resistance protein by long-term fractionated radiotherapy sensitizes lung adenocarcinoma to SN-38.2021Investigational new drugs
  49. Serum exosomal microRNAs as predictive markers for EGFR mutations in non-small-cell lung cancer.2021Journal of clinical laboratory analysisFree full text
  50. Sulforaphane overcomes T790M-mediated gefitinib resistance in vitro through epithelial-mesenchymal transition.2021Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  51. hsa_circ_0058357 acts as a ceRNA to promote non‑small cell lung cancer progression via the hsa‑miR‑24‑3p/AVL9 axis.2021Molecular medicine reportsFree full text
Chinese-language papers (not in the count)4
  1. [Intestinal Flora Dysregulation and Lung Cancer: 
Mechanism Analysis and Clinical Application].2025Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  2. [Establishment of Human Lung Adenocarcinoma Radioresistant Cell Lines
and the Mechanism of Radioresistance].2023Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  3. [Research Progress in CircRNA and Radiotherapy Resistance of Non-small Cell Lung Cancer].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  4. [Analysis of gut microbiome in patients with lung adenocarcinoma and lung squamous cell carcinoma].2021Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
All its trials on ClinicalTrials.gov, any status22
  1. Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant TherapyRecruitingNCT06862869Study siteStart 2025-04
  2. A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based ChemotherapyTerminatedNCT06267001Study sitePhase 3Start 2024-03
  3. Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung CancerStatus unknownNCT04749407Study siteStart 2021-02
  4. A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)Status unknownNCT04325763Study sitePhase 3Start 2020-05
  5. Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)CompletedNCT03829332Study sitePhase 3Start 2019-03
  6. M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)TerminatedNCT03840902Study sitePhase 2Start 2019-04
  7. A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung CancerStatus unknownNCT04641754Study sitePhase 2Start 2019-03
  8. Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension StudyCompletedNCT04676412Study sitePhase 3Start 2019-10
  9. A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) PatientsStatus unknownNCT03407300Study sitePhase 2Start 2018-02
  10. A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung CancerCompletedNCT03594747Study sitePhase 3Start 2018-07
  11. A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung CancerCompletedNCT03663205Study sitePhase 3Start 2018-07
  12. Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLCStatus unknownNCT03300115Study sitePhase 2Start 2017-05
  13. A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT02714608Study sitePhase 2Start 2016-05
  14. Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI TherapyStatus unknownNCT02787447Study sitePhase 2Start 2016-05
  15. A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing ChemotherapyCompletedNCT02813785Study sitePhase 3Start 2016-07
  16. A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung CancerStatus unknownNCT02787473Study sitePhase 2Start 2016-10
  17. A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)CompletedNCT02657434Study sitePhase 3Start 2016-04
  18. EGFR Mutations on ctDNA in Patients With Advanced NSCLCCompletedNCT02623257Study siteStart 2016-01
  19. ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLCStatus unknownNCT02946216Study siteStart 2016-11
  20. T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI FailureCompletedNCT02418234Study siteStart 2015-03
  21. Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung CancerStatus unknownNCT02348450Study sitePhase 4Start 2015-02
  22. Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung CancerStatus unknownNCT02215356Study sitePhase 2Start 2014-08

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 23 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
23
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 6620222023: 4420232024: 5520242025: 552025

9 hospitals in Hangzhou for pancreatic cancer192 hospitals in China for pancreatic cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Canagliflozin With Gemcitabine in Pancreatic Carcinoma
    Phase
    N/A
    Started
    2023-10
    Posted
    Registry
    NCT05903703

    Age 18 years to Not stated (registered criteria)

    Led by Hangzhou First People's HospitalHangzhou

  2. Recruiting
    Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT07006077

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Medical oncologyClinical trials / research unit

Over half of these papers are lab or animal studies.

Papers it led23
  1. Complex interplay between type 2 diabetes mellitus and pancreatic cancer: insights from observational and mendelian randomization analyses.2025BMC cancerFree full text
  2. Demystifying metabolic‒immune crosstalk: how amino acid metabolic reprogramming shapes the malignant phenotype and macrophage polarization of biliary and pancreatic tumors.2025International journal of biological sciencesFree full text
  3. Targeting RhoA expression with formononetin and salvianolic acid B to mitigate pancreatic cancer-associated endothelial cells changes.2025Journal of ethnopharmacology
  4. Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its ubiquitination-mediated degradation.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  5. Diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration-based cytology for distinguishing malignant and benign pancreatic cystic lesions: A systematic review and meta-analysis.2025PloS oneFree full text
  6. The role of vascular resection and reconstruction in pancreaticoduodenectomy.2024Asian journal of surgery
  7. The characteristic "alveolus nest sign" in solid pseudopapillary neoplasm of the pancreas.2024EndoscopyFree full text
  8. Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and trigger endoplasmic reticulum stress.2024International immunopharmacology
  9. A pancreaticogastric fistula related to intraductal papillary mucinous neoplasm of the pancreas developed during follow-up: A case report and literature review.2024Journal of digestive diseases
  10. Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8+T cell function and its impact against pancreatic ductal adenocarcinoma.2024OncoimmunologyFree full text
  11. Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis.2023Biochemical pharmacology
  12. KNTC1 as a putative tumor oncogene in pancreatic cancer.2023Journal of cancer research and clinical oncologyFree full text
  13. m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway.2023Journal of experimental & clinical cancer research : CRFree full text
  14. PDZ-binding kinase aggravates pancreatic neuroendocrine neoplasm progression by activating the AKT/mTOR pathway.2023Molecular carcinogenesis
  15. The net parenchymal thickness predicts pancreatic fistula after pancreaticoduodenectomy: a retrospective cohort study of objective data.2022ANZ journal of surgery
  16. CDC25C is a prognostic biomarker and correlated with mitochondrial homeostasis in pancreatic adenocarcinoma.2022BioengineeredFree full text
  17. Selective radical resection for unresectable pancreatic cancer.2022Cirugia y cirujanos
  18. CD44V3, an Alternatively Spliced Form of CD44, Promotes Pancreatic Cancer Progression.2022International journal of molecular sciencesFree full text
  19. Inhibition of TRIM32 by ibr-7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway.2022Journal of cellular and molecular medicineFree full text
  20. Immunological role and prognostic value of SPARCL1 in pan-cancer analysis.2022Pathology oncology research : PORFree full text
  21. The MYEOV-MYC association promotes oncogenic miR-17/93-5p expression in pancreatic ductal adenocarcinoma.2021Cell death & diseaseFree full text
  22. Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.2021Frontiers in immunologyFree full text
  23. EIF3B promotes cancer progression in pancreatic cancer.2021Scandinavian journal of gastroenterology
All its trials on ClinicalTrials.gov, any status3
  1. Canagliflozin With Gemcitabine in Pancreatic CarcinomaNot yet recruitingNCT05903703Lead (inferred)N/AStart 2023-10
  2. Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic CancerRecruitingNCT07006077Study sitePhase 2Start 2025-05
  3. EUS-RFA for Unresectable Pancreatic CancerCompletedNCT04310111Study siteN/AStart 2020-03

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 21 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
21
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 2220232024: 9920242025: 552025

9 hospitals in Hangzhou for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
    Phase
    N/A
    Started
    2023-07
    Posted
    Registry
    NCT07920094

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sir Run Run Shaw Hospital; 10 listed hospitals as study sitesHangzhou, Jinhua, Ningbo, Taizhou, Wenzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePathology / laboratory medicineMedical oncology
Papers it led21
  1. Effects of Continuous Perioperative Esketamine Infusion on Postoperative Depression in Breast Cancer Patients: A Randomized Controlled Double-Blind Trial.2025Drug design, development and therapyRCTFree full text
  2. Predicting Pathological Characteristics of HER2-Positive Breast Cancer from Ultrasound Images: a Deep Ensemble Approach.2025Journal of imaging informatics in medicineFree full text
  3. Pan-cancer analysis reveals BAF complexes as immune-related biomarkers and validation in triple-negative breast cancer.2025Life sciences
  4. AI in breast imaging: A systematic review of reader studies evaluating design, performance, and clinical impact.2025Medical physics
  5. Using artificial intelligence system for assisting the classification of breast ultrasound glandular tissue components in dense breast tissue.2025Scientific reportsFree full text
  6. Patient-Reported Outcomes and Complication Profiles of Implant-Based Breast Reconstruction in Patients With Postmastectomy Radiation Therapy.2024Annals of plastic surgery
  7. Nomogram based on multimodal ultrasound features for evaluating breast nonmass lesions: a single center study.2024BMC medical imagingFree full text
  8. Detection and diagnosis of automated breast ultrasound in patients with BI-RADS category 4 microcalcifications: a retrospective study.2024BMC medical imagingFree full text
  9. The mechanism and therapeutic potential of lncRNA MIR497HG/miR-16-5p axis in breast cancer.2024BMC women's healthFree full text
  10. Encapsulated Papillary Carcinoma of the Breast: A Review of Clinicopathologic Characteristics, Molecular Mechanisms, and Patient Management.2024Cancer control : journal of the Moffitt Cancer CenterFree full text
  11. ER-positive and BRCA2-mutated breast cancer: a literature review.2024European journal of medical researchFree full text
  12. Novel immunotherapies for breast cancer: Focus on 2023 findings.2024International immunopharmacology
  13. Functions and mechanisms of RNA m6A regulators in breast cancer (Review).2024International journal of oncologyFree full text
  14. Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US.2024Scientific reportsFree full text
  15. Value of multimodal imaging in the diagnosis of breast sclerosing adenosis associated with malignant lesions.2023Journal of clinical ultrasound : JCU
  16. Accelerated Perioperative Rehabilitation for Breast Cancer Patients Undergoing Radical Mastectomy: A Systematic Review.2023Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses
  17. Nodular fasciitis of the breast: the report of three cases.2022BMC women's healthFree full text
  18. β-elemene induced apoptosis and senescence of triple-negative breast cancer cells through IGF1/IGF1R pathway.2022Tissue & cell
  19. Value of quantitative sound touch elastography of tissues around breast lesions in the evaluation of malignancy.2021Clinical radiology
  20. Astragaloside IV inhibits cell proliferation and metastasis of breast cancer via promoting the long noncoding RNA TRHDE-AS1.2021Journal of natural medicines
  21. All-Trans Retinoic Acid and Doxorubicin Delivery by Folic Acid Modified Polymeric Micelles for the Modulation of Pin1-Mediated DOX-Induced Breast Cancer Stemness and Metastasis.2021Molecular pharmaceutics
All its trials on ClinicalTrials.gov, any status8
  1. Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving SurgeryRecruitingNCT07920094Study siteN/AStart 2023-07
  2. Fertility Decision and Outcomes in Young Women With Breast CancerActive, not recruitingNCT07804745Study siteStart 2025-10
  3. A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast CancerActive, not recruitingNCT06561607Study sitePhase 3Start 2024-10
  4. Exploring a Breast Cancer Early Screening Model Based on cfDNACompletedNCT06016790Study siteStart 2023-04
  5. To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast CancerActive, not recruitingNCT05365178Study sitePhase 3Start 2022-07
  6. Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoop® Bra(COSTA)Status unknownNCT03589924Study siteN/AStart 2018-06
  7. Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast CancerCompletedNCT03084939Study sitePhase 3Start 2017-04
  8. A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerCompletedNCT02896855Study sitePhase 3Start 2016-09

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 8 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.1%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 3320242025: 222025

9 hospitals in Hangzhou for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryClinical trials / research unitPediatrics

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

5 hospitals in Hangzhou for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

20 hospitals in Hangzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

12 hospitals in Hangzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 5 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.3%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025

9 hospitals in Hangzhou for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskBispecific & antibody drugsRelapse & resistance

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 7 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 332025

8 hospitals in Hangzhou for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT07022223

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou

  2. Recruiting
    ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06378138

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi

  3. Recruiting
    Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06520163

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated People's Hospital of Ningbo University; 3 listed hospitals as study sitesHangzhou, Ningbo, Wenzhou

  4. Recruiting
    Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06521255

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou

  5. Recruiting
    A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
    Phase
    Phase 1
    Started
    2023-10
    Posted
    Registry
    NCT05892718

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led7
  1. Bi-targeting of thioredoxin 1 and telomerase by thiotert promotes cell death of myelodysplastic syndromes and lymphoma.2025Biology directFree full text
  2. Multiplexed imaging mass cytometry elicits p-S6 as a therapeutic and prognostic factor in diffuse large B-cell lymphoma.2025Blood advancesFree full text
  3. Overcoming missed diagnoses of primary central nervous system Lymphoma-The key role of cerebrospinal fluid cytology: a case report.2025Diagnostic pathologyFree full text
  4. SNCA is a potential therapeutic target for COVID-19 infection in diffuse large B-cell lymphoma patients.2024Apoptosis : an international journal on programmed cell deathFree full text
  5. DLD is a potential therapeutic target for COVID-19 infection in diffuse large B-cell lymphoma patients.2024Apoptosis : an international journal on programmed cell deathFree full text
  6. Successful Treatment of Atopic Dermatitis with Dupilumab in a Patient with Non-Hodgkin's Lymphoma.2022Acta dermato-venereologicaFree full text
  7. Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report.2021Immunotherapy
Chinese-language papers (not in the count)1
  1. [Thromboelastography Combined with Blood D-Dimer in the Prediction of Lower Extremity Venous Thrombosis in Patients with Diffuse Large B-Cell Lymphoma].2025Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status8
  1. Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone LymphomaRecruitingNCT07022223Study sitePhase 2Start 2025-03
  2. Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for LymphomaRecruitingNCT06520163Study sitePhase 3Start 2024-08
  3. ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)RecruitingNCT06378138Study sitePhase 2/Phase 3Start 2024-05
  4. Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06521255Study sitePhase 3Start 2024-05
  5. A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological TumorsRecruitingNCT05892718Study sitePhase 1Start 2023-10
  6. Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCLStatus unknownNCT05186558Study sitePhase 2Start 2022-05
  7. HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT05190068Study sitePhase 1Start 2022-01
  8. An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular LymphomaCompletedNCT01340443Study siteStart 2011-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 16 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.3%.

Papers led
16
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 4420222023: 2220232024: 4420242025: 332025

11 hospitals in Hangzhou for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
    Phase
    Phase 4
    Started
    2025-11
    Posted
    Registry
    NCT07110415

    Age 40 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Dalian, Daqing, Guangzhou, Guiyang, Hangzhou, Harbin, Huzhou, Jinan, Lanzhou, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Xi'an, Yantai, Yinchuan, Zhangjiakou, Zhuhai

  2. Not yet recruiting
    OPTIMized Diagnosis and Treatment System Based on AI and Multimodal Imaging Fusion for PCI (OPTIMAI-PCI)
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07855614

    Age 18 years to 80 years (registered criteria)

    Led by Zhejiang Hospital; 6 listed hospitals as study sitesHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led16
  1. Association between coronary heart disease and cardiometabolic index: a study from NHANES 1999-2018.2025BMC cardiovascular disordersFree full text
  2. Genetic mapping of serum metabolome to chronic diseases among Han Chinese.2025Cell genomicsFree full text
  3. Comparison of Coronary Angiographic-Derived and Intracoronary Imaging-Based Fractional Flow Reserve in Assessing Coronary Artery Stenosis Severity: A Systematic Review and Network Meta-Analysis.2025Journal of evidence-based medicineFree full text
  4. Investigating the Correlation between Serum Amyloid A and Infarct-Related Artery Patency Prior to Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients.2024Angiology
  5. Quantitative Flow Ratio-Derived Index of Microcirculatory Resistance as a Novel Tool to Identify Microcirculatory Function in Patients with Ischemia and No Obstructive Coronary Artery Disease.2024CardiologyFree full text
  6. Predictive value of coronary artery computed tomography-derived fractional flow reserve for cardiovascular events in patients with coronary artery disease.2024Herz
  7. Association between personality traits and psychological distress among postmenopausal women with coronary heart disease: A cross-sectional survey and mediation analysis.2024Nursing & health sciences
  8. The Importance of Integrated Regulation Mechanism of Coronary Microvascular Function for Maintaining the Stability of Coronary Microcirculation: An Easily Overlooked Perspective.2023Advances in therapy
  9. Alterations in gut microbiota and host transcriptome of patients with coronary artery disease.2023BMC microbiologyFree full text
  10. Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease.2022BMC cardiovascular disordersFree full text
  11. The correlation between lipoprotein(a) elevations and the risk of recurrent cardiovascular events in CAD patients with different LDL-C levels.2022BMC cardiovascular disordersFree full text
  12. A comment and suggestion on angiography-derived FFR: NiFFR.2022Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  13. An attempt to better show some results such as the comparison of mortality and major adverse cardiovascular events between the abnormal and normal coronary flow reserve cohorts.2022European heart journal
  14. Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials.2021Journal of the American Heart AssociationFree full text
  15. RNA modifications in cardiovascular diseases, the potential therapeutic targets.2021Life sciences
  16. Integration of summary data from GWAS and eQTL studies identified novel risk genes for coronary artery disease.2021MedicineFree full text
Chinese-language papers (not in the count)1
  1. [Correlation of mitochondrial tRNA variants with coronary heart disease in a Chinese pedigree].2023Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
All its trials on ClinicalTrials.gov, any status7
  1. OPTIMized Diagnosis and Treatment System Based on AI and Multimodal Imaging Fusion for PCI (OPTIMAI-PCI)Not yet recruitingNCT07855614Study siteN/AStart 2026-09
  2. Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac DysfunctionRecruitingNCT07110415Study sitePhase 4Start 2025-11
  3. FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery DiseaseActive, not recruitingNCT06218485Study siteN/AStart 2024-03
  4. Wedge NC - Scoring Balloon Dilatation CatheterCompletedNCT06214247Study siteN/AStart 2021-08
  5. Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery DiseaseActive, not recruitingNCT04397211Study siteN/AStart 2020-05
  6. Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki DiseaseCompletedNCT04078568Study sitePhase 3Start 2020-01
  7. Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery DiseaseCompletedNCT01735305Study siteStart 2012-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 1 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

9 hospitals in Hangzhou for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

10 hospitals in Hangzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Posted
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

  2. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07121413

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanjing, Shanghai, Tianjin, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

10 hospitals in Hangzhou for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT06765499

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

7 hospitals in Hangzhou for Fabry disease80 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

7 hospitals in Hangzhou for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

7 hospitals in Hangzhou for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Hangzhou for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionActive, not recruitingNCT05797610Study sitePhase 3Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

7 hospitals in Hangzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Risk factors for recurrent primary biliary cirrhosis after liver transplantation: A systematic review and meta-analysis.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led no English-language PubMed papers on Leber hereditary optic neuropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Hangzhou for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

杭州市第一人民医院

Hangzhou First People's Hospital

杭州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Affiliated Hangzhou First People's Hospital; Changzhou First People's Hospital; Affiliated Hangzhou First Hospital; Affiliated Hangzhou First People Hospital; Changzhou & Changzhou First People's Hospital; Hangzhou first people's Hospital; Hangzhou First People Hospital; Changzhou First Hospital

Suggest a correctionDownload the data